focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance

Tue, 14th Jan 2014 15:22

Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks.At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts currently predict. He said that new incoming drugs from the company's portfolio as well as the buy-out of Bristol-Myers Squibb from their diabetes alliance should help halt a decline in sales. Sales have been under pressure over the last year due to a number of patent expiries and competition from generic versions of its drugs."AstraZeneca now expects 2017 revenues to be broadly in line with 2013 revenues," he said.The share price was 2.5% higher at around 3,755p by 15:50 on Tuesday.Toby Morris, Senior Sales Trader at CMC Markets, said: "The update comes ahead of a 2013 number release on Feb 6th, with a strong pipeline versus 12 months ago providing a boost in optimism and sending the stock higher."Shire, meanwhile, raised its earnings guidance for 2013 to the upper end of previous expectations, pushing the stock up 2.4% to 2,981p.Shire shares spiked immediately higher this afternoon as the Dublin-headquartered company put out a short statement from Chief Executive Flemming Ornskov that confirmed a strong finish to the year.Ornskov, who had been addressing investors at the same conference in San Francisco as AstraZeneca's Soriot, also added that he remained confident the company would deliver earnings for 2014 in line with the November 2013 consensus forecast (excluding ViroPharma).Others in the sector including Summit Corporation, Futura Medical and Skyepharma were making decent gains today.Vectura was also higher after the respiratory development company confirmed that its partner Sandoz has received Swedish marketing approval for their inhaler product AirFluSal Forspiro. Top performing sectors so far todayTechnology Hardware & Equipment 1,176.48 +1.16%Pharmaceuticals & Biotechnology 11,859.30 +0.85%Industrial Transportation 3,342.59 +0.78%Media 6,494.69 +0.73%Household Goods & Home Construction 11,269.09 +0.71%Bottom performing sectors so far todayElectronic & Electrical Equipment 4,505.01 -1.25%Industrial Metals & Mining 1,291.41 -1.24%Financial Services 7,863.20 -1.08%Oil & Gas Producers 8,257.45 -1.01%Forestry & Paper 10,922.16 -0.98%BC
More News
24 Feb 2016 12:35

Summit Therapeutics hails strong C-difficile findings

(ShareCast News) - Summit Therapeutics has reported that pre-clinical research into its treatment for the Clostridium difficile hospital superbug has found it to be a "novel and potent antibiotic". A peer-reviewed paper has been produced based on a study of Summit's ridinilazole versus current stand

Read more
19 Jan 2016 12:48

Summit Therapeutics gains worldwide patent protection for C-diff drug

(ShareCast News) - Summit Therapeutics has won a key patent protecting its novel antibiotic, ridinilazole, for the treatment of infections caused by the Clostridium difficile hospital superbug. The patent will grant Summit exclusivity in Europe for the use of ridinilazole in the treatment of CDI unt

Read more
19 Jan 2016 12:18

Summit Therapeutics Gets European Patent For Antibiotic Ridinilazole

Read more
22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

Read more
17 Dec 2015 12:28

Summit Therapeutics Third Quarter Loss Widens As Pipeline Progresses

Read more
17 Nov 2015 12:17

Summit Therapeutics Extends Alliance With University Of Oxford

Read more
18 Sep 2015 12:50

Summit Therapeutics To Present Positive SMT19969 Data In San Diego

Read more
10 Sep 2015 11:11

Summit Therapeutics Finishes Enrolment For Phase II SMT19969 Trial

Read more
27 Aug 2015 11:48

Summit Therapeutics First Half Loss Widens As It Develops Pipeline

Read more
17 Aug 2015 12:33

Summit Therapeutics surges on positive clinical trial update

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial. The drug discovery and development company said half of the

Read more
14 Jul 2015 07:25

LONDON BRIEFING: Iran Nuclear Agreement Hits Oil Prices

Read more
13 Jul 2015 11:23

Summit Therapeutics Says Preclincal Data Support Its DMD Treatment

Read more
8 Jul 2015 12:04

Summit Therapeutics receives FDA fast-track decision for new antibiotic

Drug discovery and development company Summit Therapeutics has received approval from the US and Food Drug Administration (FDA) for its novel antibiotic. The FDA granted fast-track designation for the SMT19969 antibiotic which treats both duchenne muscular dystrophy and C. difficile infection (CDI).

Read more
8 Jul 2015 11:22

Summit Therapeutics Says CDI Antibiotic Given Fast Track Designation

Read more
7 Jul 2015 11:24

Summit Therapeutics Gets European Patent For Muscle Disease Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.